Recent Quotes
My Watchlist
Indicators
Local Stocks
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Diamedica Therapeutics Inc (NQ: DMAC )

3.250 -0.010 (-0.31%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,662
Open 3.240
Bid (Size) 3.150 (1)
Ask (Size) 3.750 (20)
Prev. Close 3.260
Today's Range 3.240 - 3.360
52wk Range 1.938 - 4.069
Shares Outstanding 37,953,711
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement
From DiaMedica Therapeutics Inc.
Via Business Wire

Performance

YTD
+14.84%
+14.84%
1 Month
+40.09%
+40.09%
3 Month
+30.52%
+30.52%
6 Month
+14.04%
+14.04%
1 Year
-13.33%
-13.33%

More News

Read More
DiaMedica Therapeutics Announces $11.8 Million Private Placement
From DiaMedica Therapeutics Inc.
Via Business Wire
Recap: DiaMedica Therapeutics Q4 Earnings
Via Benzinga
Earnings Outlook For DiaMedica Therapeutics
Via Benzinga
DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia
From DiaMedica Therapeutics Inc.
Via Business Wire
DMAC Stock Earnings: DiaMedica Therapeutics Beats EPS for Q1 2024
Via InvestorPlace
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2024 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update May 9, 2024
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
From DiaMedica Therapeutics Inc.
Via Business Wire
DMAC Stock Earnings: DiaMedica Therapeutics Meets EPS for Q4 2023
Via InvestorPlace
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Attend the 14th Annual Craig-Hallum Alpha Select Conference November 16, 2023
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update November 14, 2023
From DiaMedica Therapeutics Inc.
Via Business Wire
Earnings Scheduled For November 13, 2023
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
DiaMedica Therapeutics Announces the Appointment of Ambarish Shah, Ph.D. as Chief Technology Officer
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Participate at Lake Street’s 7th Annual Best Ideas Growth Conference
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2023 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Report Second Quarter 2023 Financial Results and Provide a Business Update August 15, 2023
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Attend the American Academy of Neurology Summer Conference
From DiaMedica Therapeutics Inc.
Via Business Wire
Three (3) Stocks Under $10 That Insiders Are Buying
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.